A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

Author: Seiden M.V.   Swenerton K.D.   Matulonis U.   Campos S.   Rose P.   Batist G.   Ette E.   Garg V.   Fuller A.   Harding M.W.   Charpentier D.  

Publisher: Academic Press

ISSN: 0090-8258

Source: Gynecologic Oncology, Vol.86, Iss.3, 2002-09, pp. : 302-310

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content